



---

## TTK Healthcare LIMITED

---

TTKHC:SECL:GJ:258:19

November 07, 2019

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex  
Bandra East  
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Unaudited Financial Results along with Limited Review Report for the Second  
Quarter and Half-year ended 30<sup>th</sup> September, 2019 (Standalone)**

---

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Second Quarter and Half-Year ended 30<sup>th</sup> September, 2019 (Standalone), duly reviewed by the Audit Committee at their meeting held earlier in the day and approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully  
For TTK Healthcare Limited

**(S KALYANARAMAN)**  
*Wholtime Director & Secretary*

Encl. : a/a



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2019 (STANDALONE)

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		(Rs. in lakhs)
		(30/09/2019)	(30/06/2019)	(30/09/2018)	(30/09/2019)	(30/09/2018)	For the Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	16,485.46	17,859.06	16,609.78	34,344.52	33,922.88	62,788.36
II.	Other Income	195.15	185.70	189.77	380.85	373.12	775.35
III.	<b>Total Income (I + II)</b>	<b>16,680.61</b>	<b>18,044.76</b>	<b>16,799.55</b>	<b>34,725.37</b>	<b>34,296.00</b>	<b>63,563.71</b>
IV.	Expenses						
	(a) Cost of materials consumed	2,791.42	2,426.48	2,790.63	5,217.90	5,079.77	10,124.91
	(b) Purchase of Stock-in-trade	3,962.09	5,129.05	4,560.03	9,091.14	9,203.70	16,711.14
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(103.19)	(100.61)	(467.43)	(203.80)	(341.67)	(576.99)
	(d) Employee benefits expense	3,769.58	3,754.72	3,320.42	7,524.30	6,716.13	13,070.09
	(e) Finance Costs	75.13	68.02	94.14	143.15	199.07	337.90
	(f) Depreciation and Amortization Expense	357.86	354.44	347.66	712.30	711.48	1,466.85
	(g) Other Expenses	5,223.92	5,804.10	5,057.46	11,028.02	10,335.39	18,503.86
	<b>Total Expenses (IV)</b>	<b>16,076.81</b>	<b>17,436.20</b>	<b>15,702.91</b>	<b>33,513.01</b>	<b>31,903.87</b>	<b>59,637.76</b>
V.	<b>Profit / (Loss) before Exceptional Items and Tax (III - IV)</b>	<b>603.80</b>	<b>608.56</b>	<b>1,096.64</b>	<b>1,212.36</b>	<b>2,392.13</b>	<b>3,925.95</b>
VI.	Exceptional Items	-	-	-	-	-	-
VII.	<b>Profit / (Loss) before Tax (V - VI)</b>	<b>603.80</b>	<b>608.56</b>	<b>1,096.64</b>	<b>1,212.36</b>	<b>2,392.13</b>	<b>3,925.95</b>
VIII.	Tax Expense:						
	(1) Current Tax	69.00	238.00	400.00	307.00	890.00	1,495.00
	(2) Deferred Tax	156.73	6.63	30.80	163.36	48.49	(6.42)
IX.	<b>Profit / (Loss) for the period from Continuing Operations (VII - VIII)</b>	<b>378.07</b>	<b>363.93</b>	<b>665.84</b>	<b>742.00</b>	<b>1,453.64</b>	<b>2,437.37</b>
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expense of Discontinued Operations	-	-	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-	-	-
XIII.	<b>Profit / (Loss) for the period (IX + XII)</b>	<b>378.07</b>	<b>363.93</b>	<b>665.84</b>	<b>742.00</b>	<b>1,453.64</b>	<b>2,437.37</b>
XIV.	<b>Other Comprehensive Income:</b>						
	(A) (i) Items that will not be reclassified to profit or loss	(93.62)	(91.89)	86.66	(185.51)	28.18	234.17
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(10.35)	(6.40)	-	(16.75)	-	25.75
	(B) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV.	<b>Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]</b>	<b>274.10</b>	<b>265.64</b>	<b>752.50</b>	<b>539.74</b>	<b>1,481.82</b>	<b>2,697.29</b>
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet of previous accounting year (including Revaluation Reserve)	-	-	-	-	-	23,729.96

<b>XVI.</b>	<b>Earnings per Equity Share (For Continuing Operations):</b>						
(1)	Basic (in Rs.)	2.68	2.58	4.71	5.25	10.29	17.25
(2)	Diluted (in Rs.)	2.68	2.58	4.71	5.25	10.29	17.25
<b>XVII.</b>	<b>Earnings per Equity Share (For Discontinued Operations):</b>						
(1)	Basic (in Rs.)	-	-	-	-	-	-
(2)	Diluted (in Rs.)	-	-	-	-	-	-
<b>XVIII.</b>	<b>Earnings per Equity Share (For Continuing and Discontinued Operations):</b>						
(1)	Basic (in Rs.)	2.68	2.58	4.71	5.25	10.29	17.25
(2)	Diluted (in Rs.)	2.68	2.58	4.71	5.25	10.29	17.25

**NOTES:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 7th November, 2019 at Bengaluru.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 except for the Cash Flow Statement for the Half-year ended 30th September, 2018.
- The Company has elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised Provision for Income Tax for the Quarter and Half-year ended 30th September, 2019 and remeasured Deferred Tax Assets at the lower tax rate prescribed in the said Section. The full impact of this change has been recognised in the Profit and Loss Statement of the Current Quarter and Half-year ended 30th September, 2019.
- The Company has implemented Ind AS 116 "Leases" with effect from 1st April, 2019, using Modified Retrospective Method and electing to account for leases ending within 12 months as Short Term Leases. Effect of the same is not material except in relation to leases that had been earlier classified as finance leases applying Ind AS 17, where a sum of Rs.1,029.05 lakhs has been reclassified within Property, Plant and Equipment as Right of use Assets and Rs.35.20 lakhs has been reclassified within "Other Financial Liabilities - Current" as "Lease Liabilities - Current" and Rs.63.32 lakhs has been reclassified within "Other Financial Liabilities - Non-Current" as "Lease Liabilities - Non-Current".
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- This Statement is also available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)), National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and also on the website of the Company ([www.ttkhealthcare.com](http://www.ttkhealthcare.com)).
- Statement of Assets and Liabilities as at 30th September, 2019:**

		(Rs. in lakhs)	
Sl. No.	Particulars	As on 30/09/2019	As on 31/03/2019
<b>(A)</b>	<b>ASSETS:</b>		
<b>(I)</b>	<b>Non-Current Assets:</b>		
(a)	Property, Plant and Equipment	9,213.85	9,722.98
(b)	Capital Work-in-Progress	1,072.15	153.62
(c)	Other Intangible Assets	28.58	33.56
(d)	Financial Assets		
(i)	Investments	1,119.12	1,304.63
(ii)	Other Financial Assets	196.22	219.20
(e)	Non-current Tax Assets (Net)	1,948.38	2,049.32
(f)	Deferred Tax Assets (Net)	307.20	487.32
(g)	Other Non-current Assets	214.77	438.60
	<b>Total Non-Current Assets</b>	<b>14,100.27</b>	<b>14,409.23</b>
<b>(II)</b>	<b>Current Assets:</b>		
(a)	Inventories	5,990.02	5,530.91
(b)	Financial Assets		
(i)	Investments	-	-
(ii)	Trade Receivables	9,432.44	8,024.51
(iii)	Cash and Cash Equivalents	1,588.78	1,115.45
(iv)	Bank balances other than (iii) above	11,353.88	11,446.33
(v)	Loans	-	-
(vi)	Other Financial Assets	624.70	529.65
(c)	Other Current Assets	601.02	525.08
	<b>Total Current Assets</b>	<b>29,590.84</b>	<b>27,171.93</b>
	<b>TOTAL ASSETS</b>	<b>43,691.11</b>	<b>41,581.16</b>

<b>(B) EQUITY AND LIABILITIES:</b>		
<b>(1) Equity</b>		
(a) Equity Share Capital	1,413.03	1,413.03
(b) Other Equity	23,417.95	23,729.96
<b>Equity attributable to owners of the Company</b>	<b>24,830.98</b>	<b>25,142.99</b>
<b>Total Equity</b>	<b>24,830.98</b>	<b>25,142.99</b>
<b>(2) Liabilities</b>		
<b>(I) Non-current Liabilities:</b>		
(a) Financial Liabilities		
(i) Other Financial Liabilities	63.32	33.39
(b) Provisions	771.07	697.23
(c) Deferred Tax Liabilities (Net)	-	-
(d) Deferred Revenue Income	170.36	-
<b>Total Non-current Liabilities</b>	<b>1,004.75</b>	<b>730.62</b>
<b>(II) Current Liabilities:</b>		
(a) Financial Liabilities		
(i) Borrowings	2,997.26	2,788.31
(ii) Trade Payables		
(A) Due to Micro and Small Enterprises Payables	1,320.19	1,772.81
(B) Due to other than Micro and Small Enterprises	7,576.35	5,499.03
(iii) Other Financial Liabilities	5,359.85	4,717.29
(b) Provisions	37.02	142.44
(c) Current Tax Liabilities (Net)	1.98	310.06
(d) Other Current Liabilities	562.73	477.61
<b>Total Current Liabilities</b>	<b>17,855.38</b>	<b>15,707.55</b>
<b>TOTAL LIABILITIES</b>	<b>18,860.13</b>	<b>16,438.17</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>43,691.11</b>	<b>41,581.16</b>

**(8) Statement of Cash Flow for the Half-year ended 30th September, 2019:**

Particulars	(Rs in lakhs)		
	For the Half-year ended		For the year ended
	(30/09/2019)	(30/09/2018)	(31/03/2019)
	Unaudited	Unaudited	Audited
<b>Cash Flow from Operating activities:</b>			
<b>Profit before tax</b>	<b>1,212.36</b>	<b>2,392.13</b>	<b>3,925.95</b>
<b>Adjustments for:</b>			
Remeasurements of defined benefit plans	-	-	(144.58)
Depreciation and amortisation Expenses	712.30	711.48	1,466.85
Interest paid	143.15	199.07	337.90
Interest received	(373.43)	(335.11)	(742.79)
(Profit) / Loss on Sale of Assets / Impairment	2.25	5.92	97.73
Dividend income	(5.33)	(4.44)	(4.49)
<b>Operating Profit before working Capital Changes:</b>	<b>1,691.30</b>	<b>2,969.05</b>	<b>4,936.57</b>
<b>Adjustments for Working Capital changes:</b>			
Inventories	(459.11)	(202.00)	(241.40)
Trade receivables	(1,407.93)	(2,846.19)	(2,490.80)
Other Receivables	(148.01)	(178.44)	81.05
Trade payables	1,624.70	1,813.62	(1,361.04)
Other liabilities	446.23	10.35	2,135.03
Deferred Revenue Income	170.36	-	-
<b>Cash generated from operations</b>	<b>1,917.54</b>	<b>1,566.39</b>	<b>3,059.41</b>
Less: Direct Taxes Paid	514.15	557.09	1,328.72
<b>Net Cash generated from (used in) Operating Activities</b>	<b>1,403.39</b>	<b>1,009.30</b>	<b>1,730.69</b>

<b>Cash Flow from Investing Activities:</b>			
Purchase of Fixed Assets / Capital advances	(645.40)	(259.80)	(432.84)
Sale of Fixed Assets	0.14	1.09	1.94
Investments in Bank deposits (Net)	92.45	1,598.98	648.94
Interest received	373.43	335.11	742.79
Dividend Received	5.33	4.44	4.49
<b>Net Cash generated from (used in) investing Activities</b>	<b>(174.05)</b>	<b>1,679.82</b>	<b>965.32</b>
<b>Cash Flow from Financing Activities:</b>			
Borrowings (Net of repayment)	238.88	(1,767.34)	(1,883.24)
Interest Paid	(143.15)	(199.07)	(337.90)
Dividend Paid	(851.74)	(851.74)	(851.74)
<b>Net Cash generated from (used in) Financing Activities</b>	<b>(756.01)</b>	<b>(2,818.15)</b>	<b>(3,072.88)</b>
Net Increase / (Decrease) in Cash and Cash Equivalents	473.33	(129.03)	(376.87)
Cash and Cash Equivalents as at the beginning of the year	1,115.45	1,492.32	1,492.32
<b>Total</b>	<b>1,588.78</b>	<b>1,363.29</b>	<b>1,115.45</b>
<b>Cash and Cash Equivalents as at the end of the period / year (as per Balance Sheet)</b>	<b>1,588.78</b>	<b>1,363.29</b>	<b>1,115.45</b>

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN

Place : Bengaluru  
Date : November 07, 2019



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2019

Sl. No.	Particulars	(Rs. in lakhs)					
		For the Quarter ended			For the Half-year ended		For the Year ended
		(30/09/2019)	(30/06/2019)	(30/09/2018)	(30/09/2019)	(30/09/2018)	(31/03/2019)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	<b>Segment Revenue:</b> <b>(Sales and Other Operating Income)</b>						
(a)	Pharmaceuticals	6,175.20	6,026.58	5,916.44	12,201.78	11,470.07	21,645.89
(b)	Consumer Products	4,339.52	6,127.36	4,708.29	10,466.88	10,967.29	18,999.26
(c)	Medical Devices	1,137.88	1,199.41	1,038.19	2,337.29	2,171.99	4,286.97
(d)	Protective Devices	2,637.04	2,293.95	2,937.40	4,930.99	5,687.35	10,313.83
(e)	Foods	2,185.97	2,180.83	1,997.37	4,366.80	3,592.90	7,470.06
(f)	Others	9.85	30.93	12.09	40.78	33.28	72.35
	<b>Total</b>	<b>16,485.46</b>	<b>17,859.06</b>	<b>16,609.78</b>	<b>34,344.52</b>	<b>33,922.88</b>	<b>62,788.36</b>
	<b>Less : Inter Segment Revenue</b>	-	-	-	-	-	-
	<b>Net Sales / Income from Operations</b>	<b>16,485.46</b>	<b>17,859.06</b>	<b>16,609.78</b>	<b>34,344.52</b>	<b>33,922.88</b>	<b>62,788.36</b>
2.	<b>Segment Results:</b> <b>[Profit (+) / Loss (-) before tax and interest from each segment]</b>						
(a)	Pharmaceuticals	720.09	515.18	732.53	1,235.27	1,156.55	2,110.62
(b)	Consumer Products	511.70	605.46	821.02	1,117.16	1,951.02	3,324.73
(c)	Medical Devices	201.53	207.38	222.80	408.91	497.81	935.26
(d)	Protective Devices	(260.39)	(163.29)	(165.01)	(423.68)	(170.18)	(262.84)
(e)	Foods	(246.65)	(254.55)	(137.98)	(501.20)	(315.11)	(847.21)
(f)	Others	6.70	15.75	5.64	22.45	16.32	44.13
	<b>Total</b>	<b>932.98</b>	<b>925.93</b>	<b>1,479.00</b>	<b>1,858.91</b>	<b>3,136.41</b>	<b>5,304.69</b>
	<b>Less : Finance Cost</b>	75.13	68.02	94.14	143.15	199.07	337.90
	<b>Less : Unallocable Expenses (Net of Unallocable Income)</b>	254.05	249.35	288.22	503.40	545.21	1,040.84
	<b>Total Profit (+) / Loss (-) before tax</b>	<b>603.80</b>	<b>608.56</b>	<b>1,096.64</b>	<b>1,212.36</b>	<b>2,392.13</b>	<b>3,925.95</b>
		<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>
		<b>30/09/2019</b>	<b>30/06/2019</b>	<b>30/09/2018</b>	<b>30/09/2019</b>	<b>30/09/2018</b>	<b>31/03/2019</b>
3.	<b>Segment Assets</b>						
(a)	Pharmaceuticals	6,789.98	6,575.60	5,635.26	6,789.98	5,635.26	5,627.36
(b)	Consumer Products	3,607.54	4,424.77	3,335.11	3,607.54	3,335.11	3,229.20
(c)	Medical Devices	4,255.02	4,275.66	3,879.95	4,255.02	3,879.95	4,018.25
(d)	Protective Devices	8,429.43	8,368.60	8,666.24	8,429.43	8,666.24	8,009.33
(e)	Foods	8,522.28	9,187.44	9,645.43	8,522.28	9,645.43	8,918.46
(f)	Others	140.75	144.30	93.31	140.75	93.31	122.11
	<b>Total</b>	<b>31,745.00</b>	<b>32,976.37</b>	<b>31,255.30</b>	<b>31,745.00</b>	<b>31,255.30</b>	<b>29,924.71</b>
	<b>Unallocated</b>	15,520.33	14,782.23	13,800.95	15,520.33	13,800.95	14,250.03
	<b>Total Assets</b>	<b>47,265.33</b>	<b>47,758.60</b>	<b>45,056.25</b>	<b>47,265.33</b>	<b>45,056.25</b>	<b>44,174.74</b>
4.	<b>Segment Liabilities</b>						
(a)	Pharmaceuticals	6,196.95	6,248.87	5,006.86	6,196.95	5,006.86	5,188.06
(b)	Consumer Products	4,518.49	5,639.67	4,999.14	4,518.49	4,999.14	4,771.64
(c)	Medical Devices	1,052.09	971.99	919.14	1,052.09	919.14	865.09
(d)	Protective Devices	2,386.02	1,952.05	2,245.02	2,386.02	2,245.02	1,413.48
(e)	Foods	1,513.19	1,169.33	1,072.35	1,513.19	1,072.35	903.64
(f)	Others	134.16	144.74	137.43	134.16	137.43	138.01
	<b>Total</b>	<b>15,800.90</b>	<b>16,126.65</b>	<b>14,379.94</b>	<b>15,800.90</b>	<b>14,379.94</b>	<b>13,279.92</b>
	<b>Unallocated</b>	5,062.49	4,993.48	5,223.37	5,062.49	5,223.37	4,755.49
	<b>Total Liabilities</b>	<b>20,863.39</b>	<b>21,120.13</b>	<b>19,603.31</b>	<b>20,863.39</b>	<b>19,603.31</b>	<b>18,035.41</b>

**NOTES:**

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
  - ❖ Pharmaceuticals include products for both Human and Veterinary use.
  - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
  - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
  - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
  - ❖ Foods comprise manufacturing and marketing of Food Products.
  - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

**For TTK HEALTHCARE LIMITED**

  
**T T RAGHUNATHAN**  
**EXECUTIVE VICE CHAIRMAN**

**Place : Bengaluru**  
**Date : November 07, 2019**



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2019 (STANDALONE)

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		For the Year ended
		(30/09/2019)	(30/06/2019)	(30/09/2018)	(30/09/2019)	(30/09/2018)	(31/03/2019)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Total Income from Operations	16,485.46	17,859.06	16,609.78	34,344.52	33,922.88	62,788.36
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	603.80	608.56	1,096.64	1,212.36	2,392.13	3,925.95
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	603.80	608.56	1,096.64	1,212.36	2,392.13	3,925.95
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	378.07	363.93	665.84	742.00	1,453.64	2,437.37
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	274.10	265.64	752.50	539.74	1,481.82	2,697.29
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per the Balance Sheet of previous accounting year	-	-	-	-	-	23,729.96
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
(a)	Basic (in Rs.)	2.68	2.58	4.71	5.25	10.29	17.25
(b)	Diluted (in Rs.)	2.68	2.58	4.71	5.25	10.29	17.25

### NOTES:

- The above is an extract of the detailed Statement of Unaudited Financial Results for the Second Quarter and Half-year ended 30th September, 2019, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The full financial results for the Second Quarter and Half-year ended 30th September, 2019 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- These financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 7th November, 2019 at Bengaluru.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Company has elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised Provision for Income Tax for the Quarter and Half-year ended 30th September, 2019 and remeasured Deferred Tax Assets at the lower tax rate prescribed in the said Section. The full impact of this change has been recognised in the Profit and Loss Statement of the Current Quarter and Half-year ended 30th September, 2019.
- The Company has implemented Ind AS 116 "Leases" with effect from 1st April, 2019, using Modified Retrospective Method and electing to account for leases ending within 12 months as Short Term Leases. Effect of the same is not material except in relation to leases that had been earlier classified as finance leases applying Ind AS 17, where a sum of Rs.1,029.05 lakhs has been reclassified within Property, Plant and Equipment as Right of use Assets and Rs.35.20 lakhs has been reclassified within "Other Financial Liabilities - Current" as "Lease Liabilities - Current" and Rs.63.32 lakhs has been reclassified within "Other Financial Liabilities - Non-Current" as "Lease Liabilities - Non-Current".
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's/ year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN

Place : Bengaluru  
Date : November 07, 2019



# PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

## Independent Auditor's Review Report on review of Interim financial results

### To the Board of Directors of TTK Healthcare Limited

We have reviewed the accompanying Statement of Unaudited financial results ("the Statement") of TTK Healthcare Limited ("the Company") for the quarter and half year ended 30<sup>th</sup> September 2019. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing obligations) which has been initialed by us for identification purposes.

Attention is drawn to Note 2 of the Statement which states that the Statement of Cash Flows for the corresponding period from 1<sup>st</sup> April 2018 to 30<sup>th</sup> September 2018, as reported in the accompanying Statement has been approved by the Board of Directors of the Company, but has not been subjected to our review.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No. 003990S/S200018

  
S. Rajeshwari

Partner

Membership No. 024105

Place: Bengaluru

Date: 07-11-2019

UDIN No: 19024105AAAADK6173